dcAdoMet (decarboxylated S-adenosylmethionine) is an essential intermediate in the synthesis of polyamines. Its content is normally very low, amounting to less than 5 % of that of S-adenosylmethionine itself. It was found that in mice lacking spermine synthase there was a large increase in dcAdoMet and that overexpression of spermine synthase reduced the amount of this nucleoside. There was also an increase in dcAdoMet in cells derived from patients with Snyder-Robinson syndrome, a rare X-linked recessive human disease caused by SMS gene mutations that greatly reduce the content of spermine synthase.
INTRODUCTION
Polyamines are small basic molecules found in virtually all living cells and are essential for normal growth and development in mammals [1] . The mammalian polyamine biosynthetic pathway involves the sequential addition of aminopropyl groups to putrescine and spermidine catalysed by aminopropyltransferases that use dcAdoMet [decarboxylated AdoMet (S-adenosylmethionine); S-adenosyl-1-(methylthio) -3- propylamine] as a substrate [2] [3] [4] . This nucleoside is formed from AdoMet by the action of AdoMetDC (AdoMet decarboxylase). Once decarboxylated, AdoMet is irreversibly committed to polyamine synthesis, since methyltransferases do not use dcAdoMet as a substrate [3, [5] [6] [7] [8] . Therefore, the formation of dcAdoMet is normally linked closely to the need for polyamine synthesis. The activity of mammalian AdoMetDC is highly regulated at multiple levels, including transcription and translation (repressed by polyamines), protein turnover (increased by polyamines) and direct activation of the enzyme by putrescine [9] [10] [11] [12] [13] [14] . It is also possible that interactions between spermine synthase and AdoMetDC may influence dcAdoMet levels since the crystal structure of human spermine synthase indicates that it has an N-terminal domain with a structure that has a high degree of similarity to AdoMetDC [15] . This domain is conserved in vertebrates and is present in spermine synthases from a number of other species, but is not present in other aminopropyltransferases such as spermidine synthase [8, 16] .
Under normal physiological conditions, the steady-state level of dcAdoMet is kept very low (approx. 1-2 % of the AdoMet content in mammals) [17, 18] . It has been shown previously that perturbation of the polyamine biosynthetic pathway by drugs can drastically change the amount of dcAdoMet. Treatment with DFMO (α-difluoromethylornithine), an inhibitor of ODC (ornithine decarboxylase) that shuts off production of putrescine and leads to a dramatic fall in both putrescine and spermidine, results in a large increase in the dcAdoMet level. This increase can amount to more than 100-fold, leading to levels 3-4-fold higher than AdoMet itself [6, 19, 20] . It is caused by the absence of the amine substrate for the aminopropyltransferase reaction along with an increase in the amount and activity of AdoMetDC, which occurs in response to the reduced polyamine content.
After DFMO treatment, there is also the appearance of an acetylated derivative of dcAdoMet, Ac-dcAdoMet [S-adenosyl-1-(methylthio)-3-acetylpropylamine] [21, 22] . This accumulation is rapidly reversed by the action of a deacetylase when polyamine synthesis is allowed to resume, although the enzymes responsible for the synthesis and degradation of Ac-dcAdoMet have not been characterized.
DFMO, which is highly antiproliferative when added to cell cultures, is used to treat African sleeping sickness [23, 24] and to prevent unwanted facial hair growth [25] and has shown great promise as a cancer chemotherapeutic agent [26] . It is possible that the profound changes in the AdoMet/dcAdoMet pool that occur after DFMO may influence the effects of this drug. Although the capacity of AdoMet synthase to produce additional AdoMet is adequate to maintain a normal or near normal content of AdoMet, the total pool is increased by up to 3-4-fold, with dcAdoMet levels substantially higher than those of AdoMet. This could influence some methylase reactions, such as DNA methylation, since dcAdoMet is a known inhibitor [6] . Also, the extra synthesis of AdoMet uses substantial amounts of ATP and methionine in a futile manner.
There are no published studies on the potential physiological changes associated with the increased accumulation of dcAdoMet or of the effects of changes in the levels of other polyamine biosynthetic enzymes on its content. This is of particular interest with regard to changes in spermine synthase, which, as described above, has a domain with a very similar structure of AdoMetDC. The absence of spermine synthase in male mice, caused by a deletion of part of the X chromosome [27, 28] , leads to a severe phenotype (Gy) that includes reduced bone density, a tendency to sudden death, small size, sterility, deafness, a tendency to circling behaviour (hence the name Gyro) and other neurological symptoms [29, 30] . A rare X-linked recessive human disease, SRS (Snyder-Robinson syndrome), is caused by SMS gene mutations that greatly reduce the content of spermine synthase either via a splice site alteration that leads to premature truncation of most of the protein [31] or via point mutations that destabilize the protein [32, 33] . Affected males have mental retardation, hypotonia and movement disorders as well as bone-related abnormalities, including an asthenic habitus, skeletal defects, osteoporosis and facial asymmetry.
In the present paper, we have measured dcAdoMet levels in mouse tissues from a variety of mouse models in which polyamine metabolism is perturbed by alterations in the content of biosynthetic enzymes or regulatory molecules. These models include Gy mice that lack all spermine synthase and CAG-SMS transgenic mice that greatly overexpress this enzyme. We have also measured dcAdoMet content in cells from SRS patients. The results show that there is an inverse relationship between the levels of this nucleoside and the activity of spermine synthase.
EXPERIMENTAL

Materials
The protease inhibitor cocktail was from CalbiochemNovabiochem. Restriction enzymes and Taq polymerase were from Promega and New England Biolabs. Deoxynucleotide triphosphates were from Amersham Pharmacia. S-Adenosyl-L-[carboxyl-
14 C]methionine (58 mCi/mmol) was obtained from Amersham Pharmacia Biotech. Genomic DNA isolation kits, isoprenaline, AdoMet and all other chemicals were from Sigma. Authentic dcAdoMet was a gift from Professor A. Shirahata (Josai University, Sakado, Saitama, Japan).
Enzyme assays and dcAdoMet analyses
Tissue was homogenized in 0.5 ml of ice-cold 25 mM Tris/HCl, pH 7.5, 2.5 mM putrescine, 2.5 mM DTT (dithiothreitol), 0.1 mM EDTA, 0.01 % Tween 80 (Fisher Scientific) and protease inhibitor cocktail [500 μM 4-(2-aminoethyl)benzenesulfonylfluoride · HCl, 150 nM aprotinin, 1 μM E-64 protease inhibitor, 0.5 mM EDTA and 1 μM leupeptin]. The homogenate was centrifuged for 30 min at 20 000 g and 4
• C. The cytosolic fraction was subsequently used to determine AdoMetDC activity, and if necessary was stored at −80
• C before use. AdoMetDC activity was assayed by measuring the release of 14 CO 2 from S-adenosyl-L-[carboxyl- 14 C]methionine in the presence of 2.5 mM putrescine [34] .
Immunoblotting of AdoMetDC was carried out essentially as described previously [14, 35] . Cytosolic protein (10 μg) was separated by SDS/PAGE on 12.5 % gels and transferred to PVDF membranes. AdoMetDC protein was detected using a rabbit polyclonal antibody against human AdoMetDC [36] and a chemiluminescence detection system. The protein band intensity was quantified using the Gene Gnome system, with Gene Snap and Gene Tools software (Syngene Bio Imaging).
Polyamine content was determined by HPLC using an ion-pair reverse-phase HPLC separation method with post-column derivatization using o-phthalaldehyde as described previously [37] .
The content of AdoMet and dcAdoMet was determined by converting them to the fluorescent 1,N 6 -etheno derivatives by reaction with chloroacetaldehyde and separation by HPLC essentially as described by Wagner et al. [38] . Tissue samples were lysed in 20 % trichloroacetic acid at 4
• C overnight. After centrifugation (13 000 g for 10 min at 4 • C), the supernatant was collected and derivatized by the addition of chloroacetaldehyde (final concentration of 2 M) and sodium acetate (0.44 M final concentration) followed by incubation at pH 3.0 at 40
• C for 7 h. The derivatized samples were then analysed by HPLC on an Ultrasphere IP 4.6 mm by 250 mm column (Beckman) using a mobile phase containing medium A [0.1 M NaH 2 PO 4 , 8 mM 1-octanesulfonic acid, 0.1 mM EDTA and 2 % (v/v) acetonitrile, pH 3.65] and medium B [0.2 M NaH 2 PO 4 , 8 mM 1-octanesulfonic acid and 26 % (v/v) acetonitrile, pH 4.30] using the following gradient: 25 % to 60 % medium B in 45 min, followed by 60 % to 100 % medium B in 1 min and a 100 % medium B wash for 8 min before regenerating the starting condition. The fluorescence of the etheno derivatives of AdoMet and dcAdoMet was detected with excitation at 270 nm and emission at 410 nm and the peak areas were measured. The concentrations were then determined from a standard curve of concentration against peak area that was created using known concentrations of the etheno derivatives of AdoMet and dcAdoMet. Since there was no standard for AcdcAdoMet available, it was assumed that its fluorescence was similar to that of dcAdoMet, which is in agreement with previous reports [21] .
Mice
The animal protocols were approved by the Institutional Animal Care and Use Committee of The Pennsylvania State University College of Medicine and adhere to the National Institutes of Health guidelines for the use of experimental animals. Derivation, phenotype and characteristics of the transgenic mouse strains used in the present work are described in the indicated references as follows: Gy, lacking spermine synthase [27, 28, 39] ; CAG-SMS line 8 mice, expressing human spermine synthase from a composite CMV-IE enhancer/chicken β-actin promoter [40] ; Gy/CAG-SMS mice, lacking endogenous spermine synthase, but with a transgene that expresses spermine synthase [41] ; αMHC-AdoMetDC mice, expressing human AdoMetDC in the heart from a myosin heavy chain promoter [42] ; αMHC-AZ mice, expressing rat antizyme-1 in the heart from a myosin heavy chain promoter [43] ; and αMHC-ODC mice, expressing ODC from a myosin heavy chain promoter. The Gy mice were on the B6C3H background and the CAG-SMS mice were on the B6D2 background [40, 41] . All mice, including controls for the experiment shown in Table 1 , were offspring from the XGy:CAG-SMS crosses. For the experiment shown in Table 5 , with CAG:SMS mice, control (wild-type) mice were B6D2 non-transgenic littermates. The αMHC-AdoMetDC mice used were on the B6D2 background and control (wild-type) mice for the experiments shown in Tables 3 and 5 were also on this background. The αMHC-AZ and αMHC-ODC mice were on the C57BL/6 background and control (wild-type) mice for the experiment shown in Table 3 were also on this background.
Adult mice, 7-8 weeks old, were given daily intraperitoneal injections of either saline or 20 mg/kg isoprenaline in 0.9 % sterile saline as described in the legends to Tables 3 and 5 . Mice were killed at the time indicated after the last injection by CO 2 -induced asphyxia, weighed, and the hearts removed immediately. The hearts were then weighed and immediately flash-frozen in liquid N 2 . The cardiosomatic index, an indicator of cardiac hypertrophy, was calculated by dividing the heart weight (mg) by the body weight (g).
Cell cultures
Lymphoblast cultures from SRS patients and non-affected individuals were grown as previously described [31, 32] and cell pellets were used for determination of AdoMet and dcAdoMet as described above. All subjects consented as part of a research project conducted by the Greenwood Genetic Center, reviewed and approved by the Institutional Review Board of Self Regional Hospital according to the 45CFR46 code of ethics.
RESULTS AND DISCUSSION
Content of dcAdoMet in mouse tissues in which spermine synthase is absent
As previously reported, dcAdoMet levels in tissues from control mice were very low, amounting to ∼ 0.4-4 % of the AdoMet content with the highest values in kidney and the lowest in heart (Table 1 ). In Gy mice, which lack spermine synthase activity, the content of dcAdoMet was significantly increased by 10 -30-fold in liver, brain and kidney and by 150-fold in heart. In both heart and kidney, the content of dcAdoMet was increased in Gy mice to values similar to those of the parent AdoMet. There was also a significant increase in AdoMetDC activity in Gy mice [approx. 3-15-fold, with the highest increase in heart and the smallest in liver (Table 1) ]. Western blots confirmed that there was a substantial increase in AdoMetDC protein, although this increase was hard to quantify since the level in control mice was close to the limit of detection with the available antibody (results not shown). These results are consistent with the concept that a significant usage of dcAdoMet occurs via spermine synthase and/or that spermine represses AdoMetDC. Transgenic expression of spermine synthase in the Gy mice reversed all of the increases in dcAdoMet content and AdoMetDC (Table 1 ). There were no significant differences in these values between the CAG-SMS mice and the Gy/CAG-SMS mice.
Despite the changes in dcAdoMet content, there were no significant alterations in the content of AdoMet itself (Table 1 ). In brain, there was actually a modest rise in AdoMet in Gy mice, but these changes were not statistically significant.
Content of dcAdoMet in human cells from patients with spermine synthase deficiency
Measurements of dcAdoMet were also made in extracts prepared from cultures of cells from unaffected controls, female carriers and patients suffering from SRS. There was little difference in the AdoMet content of these cells (Table 2) . All values were within the range 75-170 pmol/mg protein and there was no indication of any alteration associated with SRS. However, the dcAdoMet levels were clearly higher in the patient samples (1-3 pmol/mg protein) compared with the controls (0.29-0.55 pmol/mg protein). This difference is very clearly demonstrated in the ratio of AdoMet to dcAdoMet, which was 54-74 in the SRS samples and 279-407 in the samples from controls and unaffected carriers ( Table 2) . Previous studies have shown that urinary excretion of dcAdoMet provides a convenient and sensitive method for measuring the effects of DFMO treatment in patients [20, 38] . Our results suggest that this measurement may also be useful in the identification of SRS. Recent advances in analysis of such metabolites using MS [44] would facilitate such measurements.
Our findings of elevated dcAdoMet in these samples raise the question as to whether the underlying phenotype of Gy mice and SRS patients might be related to changes in the dcAdoMet pool. Our studies, described below with mice in which cardiac levels of dcAdoMet are influenced by transgenic expression of ODC, AdoMetDC or antizyme, do not support this hypothesis with respect to the heart abnormalities in Gy mice. However, it remains possible that the other alterations in Gy mice (which include sterility, hearing loss, altered growth rate and neurological abnormalities [29, 30, 41] ) and in SRS patients (which include mental retardation, hypotonia, cerebellar circuitry dysfunction, [31, 33, 45] ) are linked to the change in dcAdoMet levels. Alteration in the brain ratio of AdoMet:dcAdoMet has the potential to affect neurological function.
Effect of increased dcAdoMet on cardiac physiology
Gy mice have a tendency to sudden death, which is likely to be due to cardiac arrhythmias [29] , and is totally prevented by crossing with the CAG-SMS mice [41] . The most probable cause of this phenotype is via the altered effects of spermine on K ir (inwardly rectifying potassium) channels [29] , but our finding of a large increase in cardiac dcAdoMet content in the Gy mice raised the possibility that this might also have deleterious effects on cardiac physiology. We therefore examined the content of dcAdoMet in αMHC-AdoMetDC mice, which express AdoMetDC in the heart from a very strong promoter that normally drives the synthesis of myosin. These mice have a >100-fold increase in AdoMetDC activity in the heart and have no overt cardiac phenotype unless challenged with isoprenaline [42] . As shown in Table 3 , dcAdoMet levels rose by >400-fold in the hearts of αMHC-AdoMetDC mice. There was also a large accumulation of a peak, which had the expected mobility based on previous studies [21] , of Ac-dcAdoMet. This material was not detected in the control mice. The total pool of dcAdoMet, including its acetylated derivative, was more than 9-fold that of the AdoMet itself, but the AdoMet content was not decreased significantly. Treatment with isoprenaline has been shown to cause increased hypertrophy and lethality in the αMHC-AdoMetDC mice [42] . Isoprenaline treatment reduced both the dcAdoMet and the AcdcAdoMet by approx. 40 %, but produced no change in AdoMet levels (Table 3) . These results indicate clearly that very high levels of dcAdoMet do not cause deleterious effects in the heart and rule out elevated dcAdoMet in the Gy mice as a primary contributor to cardiac hypertrophy and arrhythmias. This conclusion is supported by our observation that male offspring resulting from the cross between Gy mice and αMHC-AdoMetDC mice are viable and show no phenotypic difference or alteration in polyamine levels when compared with the Gy mice.
There was no significant alteration in AdoMet content in Gy tissues and SRS cells (Tables 1 and 2 ). It appears that there is an excess capacity to produce AdoMet that can keep up with the demand produced by the elevated dcAdoMet pool. Remarkably, this is also the case even in the αMHC-AdoMetDC mice where this pool in the heart was increased by 9-fold and there is little change in the total polyamine content. It is therefore unlikely that any pathophysiological effects of increased dcAdoMet accumulation are related to a lack of AdoMet content. However, it cannot be ruled out that the presence of high levels of dcAdoMet interferes with the use of AdoMet for methylation or other cellular reactions using this nucleoside.
Effect of ODC and antizyme on cardiac dcAdoMet and AdoMetDC
We have also found that transgenic expression of antizyme, a negative regulator of ODC [46, 47] , using the same αMHC-promoter [43] produces a large increase (>500-fold) in the content of dcAdoMet and the presence of its acetylated derivative in the heart ( Table 4 ). The αMHC-AZ mice also show no significant cardiac abnormalities [43] , so these results also support the concept described above that elevated dcAdoMet is not related to the cardiac phenotype of Gy mice. The large increase in dcAdoMet levels in αMHC-AZ mice expressing high levels of the ODC regulator antizyme in the heart is at least partly due to an increase in AdoMetDC activity. The αMHC-AZ mice exhibit at least a 90 % reduction in ODC activity, but also show a 38-fold increase in AdoMetDC activity from 1.6 + − 0.7 pmol/min per mg of protein in controls to 60.4 + − 15.7 pmol/min per mg of protein in αMHC-AZ. The increase in dcAdoMet was not seen when the αMHC-AZ mice were bred with αMHC-ODC mice, which express high levels of a stable form of ODC that forms a complex with the antizyme (Table 4 ) [48] . The possibility of a more direct activating regulatory link between antizyme and AdoMetDC may be worth investigating. As shown in Table 4 , there was no significant decrease in the dcAdoMet content in αMHC-ODC mice although spermidine levels were increased 4-fold [48] . However, it should be noted that spermine levels were not changed in these mice [48] .
Effect of high levels of spermine synthase on dcAdoMet content
As shown in Table 1 , there was a significant reduction of dcAdoMet levels in transgenic mice that express high levels of human spermine synthase from a ubiquitous composite CMV-IE enhancer/chicken β-actin promoter (CAG) [40] . Spermine synthase activity in these CAG-SMS mice was increased by 10-1500-fold with the lowest 10-fold increase in brain (Table 1 ) [40] . The dcAdoMet content fell significantly in all tissues of the CAG-SMS mice except brain ( Table 1 ). The AdoMetDC activity in the CAG-SMS mice was reduced significantly in liver and kidney and slightly, but not statistically significantly, in heart, but not at all in brain despite the vast increase in spermine synthase protein. These results focus attention on spermine itself rather than the spermine synthase protein in repressing AdoMetDC.
The CAG-SMS mice have a massive increase in the activity of spermine synthase in many tissues, but surprisingly there is only a modest increase in spermine [40] . Our results suggest that the most likely explanation for this is that the dcAdoMet pool is reduced to a point unable to support spermine synthesis. Although there is some dcAdoMet present in the tissues of these mice, its content is so low that it may be unavailable to spermine synthase. Studies of the mechanism of the spermidine synthase reaction using structural methods, ITC (isothermal titration calorimetry) and other binding assays [3, 16] suggest that dcAdoMet is bound very tightly to this enzyme in the absence of putrescine and the molar content of putrescine is similar to that of dcAdoMet. The very low residual levels of dcAdoMet in the CAG-SMS mice may therefore be utilized preferentially by spermidine synthase. It is clear that this residual pool of dcAdoMet can be used for spermidine synthesis. Treatment of CAG-SMS mice with isoprenaline, which increases ODC and provides additional putrescine for the spermidine synthase reaction [49, 50] , led to a further reduction of dcAdoMet (Table 5) .
Relationship between spermine synthase and dcAdoMet
These results show clearly that there is a inverse relationship between the ability to synthesize spermine and the content of dcAdoMet. There was a substantial rise in dcAdoMet in Gy tissues where spermine synthase is reduced and, conversely, dcAdoMet fell in all tissues of CAG-SMS mice with elevated spermine synthase except brain (the tissue in which spermine synthase is highest in control mice). It should be noted that these changes are not caused by a general reduction in polyamine content. In fact, total polyamines in both Gy mice and SRS cells are increased because spermidine content is elevated by a greater amount than the fall in spermine. The major factor in increasing dcAdoMet levels therefore appears to be the increase in AdoMetDC activity. This increase is consistent with the concept that spermine is a stronger repressor of this enzyme than spermidine.
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